Prospects for vaccine development against Buruli disease

Expert Review of Vaccines

Volumn 2, Issue 4, 2003, Pages 561-569

  Huygen, Kris ^a  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

Bacillus Calmette Gu rin; Buruli disease; M. ulcerans; Mycolactone; Vaccines

Indexed keywords

AG85A PROTEIN; AG85B PROTEIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; BACTERIAL VACCINE; BAFILOMYCIN; BCG VACCINE; CLARITHROMYCIN; ERYTHROMYCIN; ETHAMBUTOL; MYCOBACTERIUM ULCERANS VACCINE; MYCOLACTONE; RIFAMPICIN; TACROLIMUS; UNCLASSIFIED DRUG;

AFRICA; AGE DISTRIBUTION; BACTERIAL SKIN DISEASE; BACTERIAL TRANSMISSION; BCG VACCINATION; BURULI ULCER; CLINICAL FEATURE; CLINICAL TRIAL; CROSS REACTION; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; LAKE; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SWAMP; TREATMENT OUTCOME; VACCINATION; WATER CONTAMINATION;

BACTERIAL VACCINES; BCG VACCINE; CHILD; COMMUNICABLE DISEASES; HUMANS; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM ULCERANS; VACCINATION; VACCINES, SUBUNIT;

EID: 0041733071     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.4.561     Document Type: Review

References (48)

1. Asiedu K, Scherpbier R, Raviglione M. Buruli Ulcer Mycobacterium ulcerans Infection. World Health Organization, Global Buruli Ulcer Initiative, Geneva (2000). A compilation of short chapters on epidemiology, microbiology, immunology, modern diagnostics, toxin, pathology, clinical features, prevention and economic and social impact, written by various experts in the field. Including 50 plates showing the different clinical forms. Freely accessible on the WHO Buruli website.
2. McCallum P. A new mycobacterium in man. 1. Clinical Aspects. J. Pathol. Bacteriol. 60, 93-122 (1998).
3. Group UB. Clinical features and treatment of pre-ulcerative Buruli lesions: report II. Br. Med. J. 11, 390-393 (1970).
4. Hayman J, Asiedu K. Epidemiology. In: Buruli ulcer. Mycobacterium ulcerans Infection. Asiedu KSR, Raviglione M (Eds). WHO, Global Buruli Ulcer Initiative, Geneva, 2000.
5. Amofah GK, Sagoe-Moses C, Adjei-Acquah, Frimpong EH. Buruli ulcer in Amansie West district Ghana. Trans. Royal Soc. Trop. Med. Hyg. 87(6), 644-645 (1993).
6. van der Werf TS, van der Graaf WTA, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 354, 1013-1018 (1999). Nice, short overview of the literature that offers a good introduction.
7. Stinear T, Ross BC, Davies JK et al. Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR. J. Clin. Microbiol. 37(4), 1018-1023 (1999).
8. Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 353, 986 (1999).
9. Marsollier L, Robert R, Aubry J et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl. Environ. Microbiol. 68(9), 4623-4628 (2002).
10. Fenner E Homologous and heterologous immunity in infection of mice with Mycobacterium ulcerans and Mycobacterium balnei. Am. Rev. Tuberc. Pulm. Dis. 76, 76-89 (1957). First description of experimental mouse model for M. ulcerans infection.
11. Uganda Buruli Group. BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet Jan. 18th, 111-115 (1969).
12. Gooding TM, Johnson PDR, Campbell DE et al. Immune response to infection with Mycobacterium ulcerans. Infect. Immun. 69, 1704-1707 (2001).
13. Prévot G, Bourreau E, Pascalis H et al. Differential production of systemic and intralesional IFN-γ and IL-10 in nodular and ulcerative forms of Buruli disease. Infect. Immun. resubmitted for publication (2003).
14. Gooding TM, Johnson PDR, Smith M, Kemp AS, Robins-Browne RM. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect. Immun. 70, 5562-5567 (2002).
15. Portaels F, Fonteyne P-A, De Beenhouwer H et al. Variability in 3′ end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origin of isolates. J. Clin. Microbiol. 34, 962-965 (1996).
16. Mve-Obiang A, Lee RE, Portaels F. Small PLC. Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect. Immun. 71, 774-783 (2003).
17. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Ann. Rev. Immunol. 11, 165-190 (1993).
18. George KM, Chatterjee D, Gunawardana G et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283, 854-857 (1999). Biochemical characterization of the mycolactone toxin.
19. Pimsler M, Sponsler TA, Meyers WM. Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans. J. Infect. Dis. 157, 577-580 (1988).
20. Pahlevan AA, Wright DJ, Andrews C et al. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-κB function. J. Immunol. 163, 3928-3935 (1999).
21. Snyder DS, Small PLC. Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans. Microb. Pathogen. 34(2), 91-101 (2003).
22. Caramalho I, Lopes-Carvalho T, Ostler D et al. Regulatory T-cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197, 403-411 (2003).
23. Groux H. Type 1 T-regulatory cells: their role in the control of immune response. Transplantation 75(9), 8S-12S (2003).
24. Okenu DMN, Ofielu LO, Dobos KM et al. Update on serology as a potential diagnostic method for Buruli Ulcer disease. In: Sixth WHO Advisory Group Meeting on Buruli Ulcer. (WHO Eds). Geneva, March 10-13, (2003).
25. King CH, Ashford DA, Dobos KM et al. Mycobacterium ulcerans Infection and buruli ulcer disease: emergence of a public health dilemma. In: Emerging Infections 5. Scheld WM, Craig WA, Hughes JM (Eds). ASM Press, Washington DC, USA (2001).
26. Smith PG, Revill WDL, Lukwago E, Rykushin YP. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans. Roy. Soc. Trop. Med Hyg. 70(5/6), 449-457 (1976).
27. Bahr GM, Chugh TD, Behbehani K et al. Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Tubercle 68(2), 105-112 (1987).
28. Tonjum T, Welty DB, Jantzen E, Small PL. Differentiation of Mycobacterium ulcerans, M. marinum and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization and 16S rRNA gene sequence analysis. J. Clin. Microbiol. 36(4), 918-925 (1998).
29. Lozès E, Oeundo E-M, Hounsossou H et al. BCG vaccine and protection against Buruli disease: results of an epidemiological survey in the endemic region of Zagnanado in Benin. (In Preparation) (2003).
30. Portaels F, Aguiar J, Debacker M et al. Prophylactic effect of Mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin. Diagn. Lab. Immunol. 9(6), 1389-1391 (2002).
31. Bloom BR, Fine PEM. The BCG experience: Implications for future Vaccines against Tuberculosis. In: Tuberculosis: Pathogenesis, Protection and Control. Bloom BR (Ed). ASM Press, Washington, DC, USA, 531-557 (1994).
32. Group KPT. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed M. leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 348(9019), 17-24 (1996).
33. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30 kD major secretory protein induce greater protective immunity against tuberculosis than conventional vaccines in a highly susceptible animal model. Proc. Natl Acad. Sci. USA 97(25), 13853-13858 (2000).
34. Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea-pig model of pulmonary tuberculosis. Infect. Immun. 71(4), 1672-1679 (2003).
35. Pym AS, Brodin P, Majlessi L et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nature Med. 9(5), 533-539 (2003).
36. Hess JH. Mycobacterium bovis Bacille Calmette-Guérin secreting listeriolysin of Listeria monocytogenes. Proc. Natl Acad. Sci. USA 95, 7648-7653 (1998).
37. Small PLC, Alford T, Mve-Obiang A. Development of a genetic system for use in Mycobacterium ulcerans: identification of genes required for biosynthesis of mycolactone. In: Sixth WHO Advisory Group Meeting on Buruli Ulcer. (WHO Eds). WHO Headquarters, Geneva (2003).
38. Wiker HG, Harboe M. The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol. Rev. 56, 648-661 (1992).
39. Belisle JT, Vissa VD, Sievert T et al. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276, 1420-1422 (1997).
40. Content J, de La Cuvellerie A, De Wit L et al. The genes coding for the antigen 85 complexes of Mycobacterium tuberculosis and Mycobacterium bovis BCG are members of a gene family: cloning, sequence determination and genomic organization of the gene coding for antigen 85-C of M. tuberculosis. Infect. Immun. 59(9), 3205-3212 (1991).
41. Launois P, DeLeys R, N'Diaye Niang M et al. T-cell epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect. Immun. 62(9), 3679-3687 (1994).
42. Huygen K, Abramowicz D, Vandenbussche P et al. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect. Immun. 60(7), 2880-2886 (1992).
43. Huygen K. Minireview: On the use of DNA vaccines for the prophylaxis of mycobacterial diseases. Infect. Immun. 71(4), 1613-1621 (2003).
44. Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 65(2), 623-629. (1997).
45. Horwitz MA, Lee BWE, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl Acad Sci. USA 92, 1530-1534 (1995).
46. Tanghe A, Content J, Van Vooren J-P, Portaels F, Huygen K. Protective efficacy of a DNA vaccine encoding Ag85A from M. bovis BCG against Buruli Ulcer. Infect. Immun. 69(9), 5403-5411 (2001).
47. Cole S, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998).
48. Stinear TP, Jenkin GA, Johnson PDR, Davies JK. Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J. Bact. 182(22), 6322-6330 (2000).